date,title,source
Oct-22-18,OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer,GlobeNewswire
Nov-01-18,OncoMed: 3Q Earnings Snapshot,Associated Press
Nov-01-18,OncoMed Announces Third Quarter 2018 Financial Results and Operational Highlights,GlobeNewswire
Nov-05-18,OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Delivered A Weaker ROE Than Its Industry,Simply Wall St.
Nov-09-18,OncoMed Announces Early Clinical Data for anti-TIGIT Antibody,GlobeNewswire
Nov-15-18,"Recent Analysis Shows Construction Partners, OptimizeRx, OncoMed Pharmaceuticals, Issuer Direct, Red Violet, and Golden Minerals Market Influences  Renewed Outlook, Key Drivers of Growth",GlobeNewswire
